1. Home
  2. CATO vs BDSX Comparison

CATO vs BDSX Comparison

Compare CATO & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cato Corporation (The)

CATO

Cato Corporation (The)

HOLD

Current Price

$3.43

Market Cap

59.2M

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$7.90

Market Cap

62.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CATO
BDSX
Founded
1946
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Precision Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.2M
62.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CATO
BDSX
Price
$3.43
$7.90
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
54.0K
4.0M
Earning Date
11-20-2025
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$660,062,000.00
$80,173,000.00
Revenue This Year
N/A
$22.01
Revenue Next Year
N/A
$26.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.29
52 Week Low
$2.19
$3.44
52 Week High
$4.92
$23.56

Technical Indicators

Market Signals
Indicator
CATO
BDSX
Relative Strength Index (RSI) 56.23 53.75
Support Level $3.36 $5.26
Resistance Level $3.61 $10.00
Average True Range (ATR) 0.19 0.99
MACD 0.06 0.25
Stochastic Oscillator 70.53 54.26

Price Performance

Historical Comparison
CATO
BDSX

About CATO Cato Corporation (The)

The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: